



Biotech Daily

Thursday January 24, 2019

Daily news on ASX-listed biotechnology companies

- * **ASX UP, BIOTECH EVEN: KAZIA UP 34%; PROTEOMICS DOWN 12%**
- * **PROTEOMICS AXES PRISM US LICENCE**
- * **VISIONEERING 2018 RECEIPTS UP 311% TO \$4.8m**
- * **CRESO PLACEMENT RAISES \$3m**
- * **CYCLOPHARM \$2.4m R&D TAX INCENTIVE, RECRUITS 100th US PATIENT**
- * **TELIX LICENCES 99M-TECHNETIUM-IP SMA FOR PROSTATE CANCER**
- * **ITL UNMARKETABLE PARCEL FACILITY BUYS BACK 166k SHARES**

MARKET REPORT

The Australian stock market was up 0.38 percent on Thursday January 24, 2019, with the ASX200 up 22.0 points to 5,865.7 points.

Thirteen of the Biotech Daily Top 40 stocks were up, 14 fell, 11 traded unchanged and two were untraded.

Kazia was the best on no news, up 13.5 cents or 34.2 percent to 53 cents with 152,326 shares traded, followed by Antisense up 13.5 percent to 4.2 cents with 2.1 million shares traded.

Cyclopharm climbed 7.1 percent; Compumedics was up 6.1 percent; Paradigm improved 5.2 percent; Opthea was up 4.9 percent; Airxpanders climbed 3.2 percent; Nanosonics and Universal Biosensors rose more than two percent; Actinogen, Cochlear, Cynata, Starpharma and Volpara climbed more than one percent; with CSL up 0.7 percent.

Proteomics led the falls, down 4.5 cents or 11.5 percent to 34.5 cents with 577,657 shares traded.

Orthocell fell 7.1 percent; Ellex, Genetic Signatures and LBT lost more than three percent; Clinuvel, Mesoblast, Oncosil and Prescient shed more than two percent; Pharmaxis and Pro Medicus were down more than one percent; with Medical Developments, Neuren, Polynovo and Resmed down by less than one percent.

PROTEOMICS INTERNATIONAL LABORATORIES

Proteomics says it has rescinded its exclusive licencing deal with the Austin, Texas-based Prismhealthdx “due to ongoing roll-out delays”.

Proteomics said it was negotiating with “a number of diagnostic and laboratory technology companies that offer larger markets and faster scale and deployment including tier 1 national diagnostic groups”.

Proteomics managing director Dr Richard Lipscombe said the decision “was necessary after it became clear that Prism was having internal operational issues that were preventing its laboratory from rolling out [the Promarkerd diabetic kidney test] in the US”. “Promarkerd is world-beating technology and needs to get into the hands of specialists and physicians to stem the tsunami of diabetic kidney disease which is causing over 40,000 deaths per year in the US, with related healthcare spending exceeding \$US100 billion annually,” Dr Lipscombe said.

“There is nothing else like Promarkerd available,” Dr Lipscombe said.

“It is the world’s leading predictive test for diabetic kidney disease according to analysts in our sector,” Dr Lipscombe said.

Proteomics said insurance companies were “keen to make the test available because it would cut dramatically the number of people unaware that they have progressive kidney disease.

Dr Lipscombe said the company needed a new partner that had “100 percent commitment to a rapid rollout in the US because that market was important to the company and the US population with diabetes deserve to know their kidney disease status”.

Proteomics fell 4.5 cents or 11.5 percent to 34.5 cents.

VISIONEERING TECHNOLOGIES

Visioneering says that receipts from customers for the 12 months to December 31, 2018 increased 310.5 percent to \$US3,403,000 (\$A4,774,360).

Visioneering said that shipments of its Naturalvue multifocal one-day contact lenses to eye care professionals increased 244 percent compared to the previous corresponding period. The company said that for the three months to December 31, 2018 it had revenue of more than \$US1 million for the second consecutive quarter, with 89 percent of eye care professionals who purchased the product in the three months to September 30, repeating orders for the fourth quarter of the year.

Visioneering said it had \$US7,275,000 in cash at December 31, with a projected cash burn of \$4,283,000 for the three months to March 31, 2019.

Visioneering was up half a cent or 2.9 percent to 17.5 cents.

CRESO PHARMA

Creso says it has raised \$3 million in a placement at 45 cents a share.

Creso said one free attaching listed option would come with every three shares, exercisable at eight cents a share by August 21, 2020.

The company said the placement was managed by Everblu Capital, who received six percent of the total funds raised, but no related parties participated.

Creso said director Adam Blumenthal was a related party to Everblu and fees payable to the company were negotiated on an arm’s length basis.

The company said funds raised would be used to accelerate sales and marketing efforts, to repay a portion of its debt and to fund expenses of the placement.

Creso fell 2.5 cents or 4.6 percent to 51.5 cents.

CYCLOPHARM

Cyclopharm says it has received \$2,390,586 million from the Australian Tax Office under the Federal Government Research and Development Tax Incentive program.

Cyclopharm said the rebate related to research and development expenditure for the year to June 30, 2018.

The company said it recruited the 100th of about 240 patients in its US phase III trial of Technegas.

Cyclopharm said it had received \$335,000 from Bjorn Altmann and Almedis Altmann GmbH, a former employee in Germany, in a legal settlement.

Cyclopharm was up eight cents or 7.1 percent to \$1.20.

TELIX PHARMACEUTICALS

Telix says it has in-licenced 99m-technetium-iPSMA for the imaging of prostate cancer from the Mexican Instituto Nacional de Investigaciones Nucleares.

Telix said the in-licencing of 99m-technetium-EDDA/HYNIC-Lys(Nal)-Urea-Glu through its wholly-owned subsidiary Advanced Nuclear Medicine Ingredients SA enabled it to offer a prostate imaging product for use with single photon emission computed tomography (SPECT).

The company said the in-licenced product was “an imaging approach and radiopharmaceutical supply chain that is far more widely available in [the Middle East and North Africa], Latin America and Asia”.

Telix said the partnership with the Instituto Nacional de Investigaciones Nucleares was a royalty-bearing licence agreement and provided manufacturing access to existing clinical-grade production of the metastable isomer of technetium-99 (99mTc) prostate specific membrane antigen kit,

The company said the licence enabled it “to rapidly add a second commercially-ready prostate imaging product to its urologic oncology portfolio”.

Telix said that 99mTc-PSMA inhibitors (99mTc-iPSMA) had “the clinical and commercial potential ... to evaluate both primary disease and metastases in regions that do not have extensive [positron emission tomography] infrastructure”.

The company said that the images obtained with 9mTc-iPSMA were “qualitatively and semi-quantitatively similar” to 68Ga-PSMA-11 with positron emission computed tomography.

Telix chief executive officer Dr Christian Behrenbruch said that positron emission tomography (PET) infrastructure was well-developed in the US and EU, PET-based nuclear medicine dominated “due to superior image quality, the quantitative nature of PET and higher reimbursement for PET-based procedures compared to traditional SPECT-based nuclear medicine procedures”.

“However, we believe that the availability of PSMA imaging is fundamental to enabling patient access to 177Lu-PSMA therapy on a global basis and therefore a kit-based approach based on 99mTc-iPSMA is a powerful addition to the product portfolio and complements our existing development of the 68Ga-PSMA illumet kit,” Dr Behrenbruch said.

Telix said that delivering SPECT PSMA to patients in countries where PET was not accessible or had limited availability, such as Asia and Latin America, would contribute to better management of prostate cancer globally.

Telix was unchanged at 75.5 cents.

[ITL HEALTH GROUP](#)

ITL says its unmarketable parcel facility has bought back 165,947 shares at 13 cents a share, representing 97 shareholdings, with about 30 parcels remaining (BD: Dec 3, 2018). ITL was unchanged at 13.5 cents.